Health Care • Medical/Dental Instruments
$19.11 ▼ -0.68
(-3.44%)
MKT CAP: $1.38B • VOL: 1.87M
52W L $12 52W H $30
TNDM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.01B | $940.2M | $747.7M |
| YoY Revenue Growth % | +7.9% | +25.7% | — |
| Gross Profit | $546.0M | $489.6M | — |
| Gross Margin % | 53.8% | 52.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$187.3M | -$99.1M | -$233.2M |
| Operating Margin % | -18.5% | -10.5% | -31.2% |
| Net Income (GAAP) | -$204.7M | -$96.0M | -$222.6M |
| EBITDA (Normalized) | -$171.3M | -$83.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$9.7M | $24.2M | -$31.8M |
| Capital Expenditures (CapEx) | $19.9M | $19.2M | — |
| Free Cash Flow (FCF) | -$29.7M | $5.0M | -$31.8M |
| FCF Margin % | -2.9% | 0.5% | -4.3% |
| Return on Invested Capital (ROIC %) | -39.5% | -15.6% | — |
| Cash & Short-Term Equivalents | $90.6M | $69.2M | — |
| Total Debt (Short + Long Term) | $310.0M | $308.3M | — |
| Total Stockholders' Equity | $155.2M | $263.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TNDM.